Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Johnson & Johnson Reports 2011 Third-Quarter Results

      Sales of $16.0 Billion increased 6.8% Versus 2010 Third-Quarter; Third Quarter EPS was $1.15

      Excluding Special Items, 2011 Third-Quarter EPS of $1.24, increased 0.8%*


      News provided by

      Johnson & Johnson

      Oct 18, 2011, 07:45 ET

      Share this article

      Share this article


      NEW BRUNSWICK, N.J., Oct. 18, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $16.0 billion for the third quarter of 2011, an increase of 6.8% as compared to the third quarter of 2010.  Operational results increased 2.6% and the positive impact of currency was 4.2%.  Domestic sales declined 3.7%.  International sales increased 16.4%, reflecting operational growth of 8.3% and a positive currency impact of 8.1%.

      Net earnings and diluted earnings per share for the third quarter of 2011 were $3.2 billion and $1.15, respectively.  Third-quarter 2011 net earnings also included an after-tax mark-to-market adjustment to the value of the currency option associated with the planned acquisition of Synthes, Inc.  Excluding special items, net earnings for the current quarter were $3.4 billion and diluted earnings per share were $1.24, representing increases of 0.8% and 0.8%, respectively, as compared to the same period in 2010.*  

      The Company updated its earnings guidance for full-year 2011 to $4.95 - $5.00 per share.  The Company's guidance excludes the impact of special items.

      "Our solid results this quarter reflect the success of many of our recently launched products," said William C. Weldon, Chairman and Chief Executive Officer.  "As we near the completion of our 125th year in business, our people continue to deliver new products, innovative pipelines and expand our global presence in ways that position us well to drive long-term growth and meet significant unmet medical and customer needs," said Weldon.

      Worldwide Consumer sales of $3.7 billion for the third quarter represented an increase of 4.9% versus the prior year consisting of an operational increase of 0.5% and a positive impact from currency of 4.4%.  Domestic sales declined 4.5%.  International sales increased 10.1%, which reflected an operational increase of 3.3% and a positive currency impact of 6.8%.

      Sales in U.S. over-the-counter medicines were significantly impacted by the suspension of manufacturing at the McNeil Consumer Healthcare facility in Fort Washington, Pa., as well as the impact on production volumes related to ongoing efforts to enhance quality and manufacturing systems.  Positive contributors to operational results were NEUTROGENA® and Dabao skin care products; international sales of oral care products; and baby care products.

      In September, McNeil-PPC, Inc. completed the acquisition of full ownership of the Johnson & Johnson-Merck Consumer Pharmaceuticals Co. in the U.S. The business will be renamed McNeil Consumer Pharmaceuticals Co. and will continue to market products under the PEPCID®, MYLANTA®, and MYLICON® brands.

      Worldwide Pharmaceutical sales of $6.0 billion for the third quarter represented an increase of 8.9% versus the prior year with operational growth of 4.9% and a positive impact from currency of 4.0%.  Domestic sales declined 6.1%.  International sales increased 27.5%, which reflected an operational increase of 18.5% and a positive currency impact of 9.0%.  

      Sales results in the U.S. were negatively impacted by generic competition for LEVAQUIN® (levofloxacin), a treatment for bacterial infections, partially offset by the strong performance of recently launched products.

      The strong performance of recently launched products, include ZYTIGA® (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone or prednisolone, for the treatment of men with metastatic, castration-resistant prostate cancer; STELARA® (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI® (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA® SUSTENNA™ (paliperidone palmitate) a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults.

      Also contributing to operational sales growth were the incremental sales from the amended distribution agreement with Merck for sales of REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; recently acquired vaccines, proteins and antibodies from Crucell that prevent and/or treat infectious diseases; PREZISTA® (darunavir), a treatment for HIV; and VELCADE® (bortezomib), a treatment for multiple myeloma.

      During the quarter, the European Commission granted full approval of the Marketing Authorization of ZYTIGA® (abiraterone acetate), a novel, once-daily, oral medication for use in combination with prednisone or prednisolone, for the treatment of metastatic castration-resistant prostate cancer.  In addition, the European Commission approved INCIVO® (telaprevir), a direct acting antiviral protease inhibitor, for the treatment of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults.

      The U.S. Food and Drug Administration (FDA) approved an additional indication for REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.  Also during the quarter, the FDA approved NUCYNTA® ER, an oral analgesic, for the management of moderate to severe chronic pain in adults.

      In September, the Company announced that the Committee for Medicinal Products for Human use of the European Medicines Agency adopted a positive opinion recommending the approval of EDURANT® (rilpivirine), a once-daily treatment in combination with other antiretroviral agents, for the treatment of human immunodeficiency virus type 1 infection in antiretroviral treatment-naive adult patients.

      Worldwide Medical Devices and Diagnostics sales of $6.3 billion for the third quarter represented an increase of 6.1% versus the prior year consisting of an operational increase of 1.7% and a positive currency impact of 4.4%.  Domestic sales declined 0.7%.  International sales increased 12.3%, which reflected an operational increase of 3.9% and a positive currency impact of 8.4%.

      Primary contributors to operational growth included Ethicon's surgical care products; Ethicon Endo-Surgery's Advanced Sterilization Products and international sales of minimally invasive products; and Biosense Webster's electrophysiology business.

      During the quarter, the FDA cleared DePuy Orthopaedics, Inc.'s TRUMATCH® Personalized Solutions System for use with the SIGMA® Fixed-Bearing Knee system.  TRUMATCH®  Personalized Solutions is a surgical instrumentation and computer software system that is designed to aid in knee implant positioning and procedure efficiency.  

      In September, Ethicon Endo-Surgery announced that it entered into a definitive agreement to acquire privately-held SterilMed, Inc., a leader in the reprocessing and remanufacturing of medical devices in the U.S.  The acquisition would broaden the Ethicon Endo-Surgery portfolio and enable expansion in a rapidly growing market segment, bringing added scale and scope.

      About Johnson & Johnson

      Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 117,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

      * Net earnings and diluted earnings per share excluding special items are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures is included in the financial schedules accompanying this press release and can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

      NOTE TO INVESTORS

      Johnson & Johnson will conduct a conference call with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

      Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's investor website at www.jnj.com

      (This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general industry conditions and competition; economic factors, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; trends toward health care cost containment; and increased scrutiny of the healthcare industry by government agencies.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 2, 2011.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

      Johnson & Johnson and Subsidiaries

      Supplementary Sales Data





















      (Unaudited; Dollars in Millions)

      THIRD QUARTER


      NINE MONTHS






      Percent Change






      Percent Change


      2011


      2010


      Total


      Operations


      Currency


      2011


      2010


      Total


      Operations


      Currency

      Sales to customers by




















      segment of business








































      Consumer




















         U.S.

      $   1,219


      1,277


      (4.5)

      %

      (4.5)


      -


      $   3,903


      4,300


      (9.2)

      %

      (9.2)


      -

         International

      2,521


      2,290


      10.1


      3.3


      6.8


      7,312


      6,680


      9.5


      2.9


      6.6


      3,740


      3,567


      4.9


      0.5


      4.4


      11,215


      10,980


      2.1


      (1.9)


      4.0





















      Pharmaceutical




















         U.S.

      2,869


      3,054


      (6.1)


      (6.1)


      -


      9,499


      9,370


      1.4


      1.4


      -

         International

      3,113


      2,441


      27.5


      18.5


      9.0


      8,775


      7,316


      19.9


      12.1


      7.8


      5,982


      5,495


      8.9


      4.9


      4.0


      18,274


      16,686


      9.5


      6.1


      3.4





















      Med Devices & Diagnostics




















         U.S.

      2,780


      2,800


      (0.7)


      (0.7)


      -


      8,521


      8,551


      (0.4)


      (0.4)


      -

         International

      3,503


      3,120


      12.3


      3.9


      8.4


      10,765


      9,726


      10.7


      3.0


      7.7


      6,283


      5,920


      6.1


      1.7


      4.4


      19,286


      18,277


      5.5


      1.4


      4.1





















      U.S.

      6,868


      7,131


      (3.7)


      (3.7)


      -


      21,923


      22,221


      (1.3)


      (1.3)


      -

      International

      9,137


      7,851


      16.4


      8.3


      8.1


      26,852


      23,722


      13.2


      5.8


      7.4

      Worldwide

      $ 16,005


      14,982


      6.8

      %

      2.6


      4.2


      $ 48,775


      45,943


      6.2

      %

      2.3


      3.9



      Johnson & Johnson and Subsidiaries

      Supplementary Sales Data





















      (Unaudited; Dollars in Millions)

      THIRD QUARTER


      NINE MONTHS






      Percent Change






      Percent Change


      2011


      2010


      Total


      Operations


      Currency


      2011


      2010


      Total


      Operations


      Currency

      Sales to customers by




















      geographic area








































      U.S.

      $   6,868


      7,131


      (3.7)

      %

      (3.7)


      -


      $ 21,923


      22,221


      (1.3)

      %

      (1.3)


      -





















      Europe

      4,124


      3,629


      13.6


      4.9


      8.7


      12,850


      11,563


      11.1


      4.0


      7.1

      Western Hemisphere excluding U.S.

      1,751


      1,424


      23.0


      17.1


      5.9


      4,730


      4,079


      16.0


      10.1


      5.9

      Asia-Pacific, Africa

      3,262


      2,798


      16.6


      8.1


      8.5


      9,272


      8,080


      14.8


      6.3


      8.5

      International

      9,137


      7,851


      16.4


      8.3


      8.1


      26,852


      23,722


      13.2


      5.8


      7.4





















      Worldwide

      $ 16,005


      14,982


      6.8

      %

      2.6


      4.2


      $ 48,775


      45,943


      6.2

      %

      2.3


      3.9



      Johnson & Johnson and Subsidiaries

      Condensed Consolidated Statement of Earnings











      (Unaudited; in Millions Except Per Share Figures)

      THIRD QUARTER












      2011


      2010


      Percent




      Percent




      Percent


      Increase


      Amount


      to Sales


      Amount


      to Sales


      (Decrease)

      Sales to customers

      $ 16,005


      100.0


      $ 14,982


      100.0


      6.8

      Cost of products sold

      5,072


      31.7


      4,594


      30.7


      10.4

      Selling, marketing and administrative expenses

      5,240


      32.7


      4,709


      31.4


      11.3

      Research and development expense

      1,773


      11.1


      1,657


      11.1


      7.0

      Interest (income)expense, net

      117


      0.7


      95


      0.6



      Other (income)expense, net

      (308)


      (1.9)


      (292)


      (2.0)



      Earnings before provision for taxes on income

      4,111


      25.7


      4,219


      28.2


      (2.6)

      Provision for taxes on income

      909


      5.7


      802


      5.4


      13.3

      Net earnings

      $   3,202


      20.0


      $   3,417


      22.8


      (6.3)











      Net earnings per share  (Diluted)

      $     1.15




      $     1.23




      (6.5)











      Average shares outstanding  (Diluted)

      2,778.2




      2,786.4















      Effective tax rate

      22.1

      %



      19.0

      %














      Adjusted earnings before provision for taxes and net earnings










          Earnings before provision for taxes on income

      $   4,427

      (1)

      27.7


      $   4,219


      28.2


      4.9

          Net earnings

      $   3,443

      (1)

      21.5


      $   3,417


      22.8


      0.8

          Net earnings per share  (Diluted)

      $     1.24

      (1)



      $     1.23




      0.8

          Effective tax rate

      22.2%




      19.0%















      (1) The $316 million difference between as reported earnings and as adjusted earnings before provision for taxes on income is the exclusion of a mark-to-market adjustment associated with a currency option and deal costs related to the planned acquisition of Synthes.  Net earnings and net earnings per share (diluted) on these items are $241 million and $0.09 per share, respectively.  



      Johnson & Johnson and Subsidiaries

      Condensed Consolidated Statement of Earnings











      (Unaudited; in Millions Except Per Share Figures)

      NINE MONTHS












      2011


      2010


      Percent




      Percent




      Percent


      Increase


      Amount


      to Sales


      Amount


      to Sales


      (Decrease)

      Sales to customers

      $ 48,775


      100.0


      $ 45,943


      100.0


      6.2

      Cost of products sold

      15,022


      30.8


      13,752


      29.9


      9.2

      Selling, marketing and administrative expenses

      15,511


      31.8


      14,244


      31.0


      8.9

      Research and development expense

      5,393


      11.0


      4,862


      10.6


      10.9

      Interest (income)expense, net

      332


      0.7


      234


      0.5



      Other (income)expense, net

      (115)


      (0.2)


      (1,868)


      (4.0)



      Restructuring expense

      589


      1.2


      -


      -



      Earnings before provision for taxes on income

      12,043


      24.7


      14,719


      32.0


      (18.2)

      Provision for taxes on income

      2,589


      5.3


      3,327


      7.2


      (22.2)

      Net earnings

      $   9,454


      19.4


      $ 11,392


      24.8


      (17.0)











      Net earnings per share  (Diluted)

      $     3.40




      $     4.08




      (16.7)











      Average shares outstanding  (Diluted)

      2,777.6




      2,792.0















      Effective tax rate

      21.5

      %



      22.6

      %














      Adjusted earnings before provision for taxes and net earnings










          Earnings before provision for taxes on income

      $ 13,696

      (1)

      28.1


      $ 13,379

      (2)

      29.1


      2.4

          Net earnings

      $ 10,738

      (1)

      22.0


      $ 10,415

      (2)

      22.7


      3.1

          Net earnings per share  (Diluted)

      $     3.87

      (1)



      $     3.73

      (2)



      3.8

          Effective tax rate

      21.6%




      22.2%















      (1) The $1,653 million difference between as reported earnings and as adjusted earnings before provision for taxes on income is the exclusion of expense due to restructuring ($676 million, of which $589 million is reported as restructuring expense and $87 million is included in cost of products sold), expense due to litigation matters ($654 million), additional DePuy ASR™ Hip recall costs ($109 million) and a mark-to-market adjustment associated with a currency option and deal costs related to the planned acquisition of Synthes ($214 million).  Net earnings and net earnings per share (diluted) on these items are $1,284 million and $0.47 per share, respectively.  

      (2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of income from net litigation of $1,340 million, $977 million and $0.35 per share, respectively.




      REPORTED SALES vs. PRIOR PERIOD ($MM)


      THIRD QUARTER


      NINE MONTHS




      % Change



      % Change


      2011

      2010

      Reported

      Operational (1)

      Currency


      2011

      2010

      Reported

      Operational (1)

      Currency

      CONSUMER SEGMENT (2)












      BABY CARE












      US

      105

      104

      1.0%

      1.0%

      -


      315

      306

      2.9%

      2.9%

      -

      Intl

      508

      462

      10.0%

      4.8%

      5.2%


      1,457

      1,326

      9.9%

      4.4%

      5.5%

      WW

      613

      566

      8.3%

      4.1%

      4.2%


      1,772

      1,632

      8.6%

      4.1%

      4.5%

      ORAL CARE












      US

      162

      164

      -1.2%

      -1.2%

      -


      483

      486

      -0.6%

      -0.6%

      -

      Intl

      260

      220

      18.2%

      11.1%

      7.1%


      729

      651

      12.0%

      4.8%

      7.2%

      WW

      422

      384

      9.9%

      5.8%

      4.1%


      1,212

      1,137

      6.6%

      2.5%

      4.1%

      OTC/NUTRITIONALS












      US

      332

      438

      -24.2%

      -24.2%

      -


      1,059

      1,472

      -28.1%

      -28.1%

      -

      Intl

      722

      671

      7.6%

      0.3%

      7.3%


      2,207

      1,985

      11.2%

      3.9%

      7.3%

      WW

      1,054

      1,109

      -5.0%

      -9.4%

      4.4%


      3,266

      3,457

      -5.5%

      -9.7%

      4.2%

      SKIN CARE












      US

      376

      311

      20.9%

      20.9%

      -


      1,251

      1,185

      5.6%

      5.6%

      -

      Intl

      567

      489

      16.0%

      8.4%

      7.6%


      1,520

      1,378

      10.3%

      3.7%

      6.6%

      WW

      943

      800

      17.9%

      13.2%

      4.7%


      2,771

      2,563

      8.1%

      4.5%

      3.6%

      WOMEN'S HEALTH












      US

      104

      121

      -14.0%

      -14.0%

      -


      350

      404

      -13.4%

      -13.4%

      -

      Intl

      354

      338

      4.7%

      -1.6%

      6.3%


      1,044

      990

      5.5%

      -0.5%

      6.0%

      WW

      458

      459

      -0.2%

      -4.8%

      4.6%


      1,394

      1,394

      0.0%

      -4.3%

      4.3%

      WOUND CARE/OTHER












      US

      140

      139

      0.7%

      0.7%

      -


      445

      447

      -0.4%

      -0.4%

      -

      Intl

      110

      110

      0.0%

      -8.2%

      8.2%


      355

      350

      1.4%

      -5.5%

      6.9%

      WW

      250

      249

      0.4%

      -2.8%

      3.2%


      800

      797

      0.4%

      -2.7%

      3.1%

      TOTAL CONSUMER












      US

      1,219

      1,277

      -4.5%

      -4.5%

      -


      3,903

      4,300

      -9.2%

      -9.2%

      -

      Intl

      2,521

      2,290

      10.1%

      3.3%

      6.8%


      7,312

      6,680

      9.5%

      2.9%

      6.6%

      WW

      3,740

      3,567

      4.9%

      0.5%

      4.4%


      11,215

      10,980

      2.1%

      -1.9%

      4.0%

























      See footnotes at end of schedule
















      REPORTED SALES vs. PRIOR PERIOD ($MM)


      THIRD QUARTER


      NINE MONTHS




      % Change




      % Change


      2011

      2010

      Reported

      Operational (1)

      Currency


      2011

      2010

      Reported

      Operational (1)

      Currency

      PHARMACEUTICAL SEGMENT  (2) (4)












      ACIPHEX/PARIET












      US

      94

      116

      -19.0%

      -19.0%

      -


      304

      356

      -14.6%

      -14.6%

      -

      Intl

      141

      124

      13.7%

      3.9%

      9.8%


      417

      398

      4.8%

      -2.8%

      7.6%

      WW

      235

      240

      -2.1%

      -7.2%

      5.1%


      721

      754

      -4.4%

      -8.4%

      4.0%

      CONCERTA/METHYLPHENIDATE












      US

      179

      214

      -16.4%

      -16.4%

      -


      667

      668

      -0.1%

      -0.1%

      -

      Intl

      104

      85

      22.4%

      13.7%

      8.7%


      327

      283

      15.5%

      7.5%

      8.0%

      WW

      283

      299

      -5.4%

      -7.9%

      2.5%


      994

      951

      4.5%

      2.1%

      2.4%

      DOXIL/CAELYX












      US

      10

      75

      -86.7%

      -86.7%

      -


      130

      225

      -42.2%

      -42.2%

      -

      Intl

      76

      10

      *

      *

      7.9%


      233

      28

      *

      *

      7.3%

      WW

      86

      85

      1.2%

      -6.1%

      7.3%


      363

      253

      43.5%

      36.8%

      6.7%

      DURAGESIC/FENTANYL TRANSDERMAL












      US

      31

      42

      -26.2%

      -26.2%

      -


      69

      117

      -41.0%

      -41.0%

      -

      Intl

      124

      142

      -12.7%

      -20.1%

      7.4%


      380

      435

      -12.6%

      -19.5%

      6.9%

      WW

      155

      184

      -15.8%

      -21.5%

      5.7%


      449

      552

      -18.7%

      -24.2%

      5.5%

      LEVAQUIN/FLOXIN












      US

      14

      274

      -94.9%

      -94.9%

      -


      585

      926

      -36.8%

      -36.8%

      -

      Intl

      11

      12

      -8.3%

      -10.7%

      2.4%


      33

      31

      6.5%

      2.7%

      3.8%

      WW

      25

      286

      -91.3%

      -91.4%

      0.1%


      618

      957

      -35.4%

      -35.5%

      0.1%

      PREZISTA












      US

      132

      102

      29.4%

      29.4%

      -


      386

      290

      33.1%

      33.1%

      -

      Intl

      184

      128

      43.8%

      36.2%

      7.6%


      509

      331

      53.8%

      47.1%

      6.7%

      WW

      316

      230

      37.4%

      31.2%

      6.2%


      895

      621

      44.1%

      38.7%

      5.4%

      PROCRIT/EPREX












      US

      176

      204

      -13.7%

      -13.7%

      -


      623

      800

      -22.1%

      -22.1%

      -

      Intl

      207

      202

      2.5%

      -5.4%

      7.9%


      632

      655

      -3.5%

      -9.8%

      6.3%

      WW

      383

      406

      -5.7%

      -9.6%

      3.9%


      1,255

      1,455

      -13.7%

      -16.5%

      2.8%

      REMICADE












      US

      876

      857

      2.2%

      2.2%

      -


      2,500

      2,420

      3.3%

      3.3%

      -

      US Exports (3)

      343

      365

      -6.0%

      -6.0%

      -


      1,360

      1,106

      23.0%

      23.0%

      -

      Intl

      189

      7

      *

      *

      6.3%


      204

      19

      *

      *

      6.9%

      WW

      1,408

      1,229

      14.6%

      13.6%

      1.0%


      4,064

      3,545

      14.6%

      14.2%

      0.4%

      RISPERDAL/RISPERIDONE












      US

      8

      (2)

      -

      -

      -


      27

      (14)

      -

      -

      -

      Intl

      120

      123

      -2.4%

      -9.7%

      7.3%


      367

      390

      -5.9%

      -12.9%

      7.0%

      WW

      128

      121

      5.8%

      -1.7%

      7.5%


      394

      376

      4.8%

      -2.5%

      7.3%

      RISPERDAL CONSTA












      US

      111

      108

      2.8%

      2.8%

      -


      335

      340

      -1.5%

      -1.5%

      -

      Intl

      279

      270

      3.3%

      -4.8%

      8.1%


      863

      772

      11.8%

      4.1%

      7.7%

      WW

      390

      378

      3.2%

      -2.6%

      5.8%


      1,198

      1,112

      7.7%

      2.4%

      5.3%

      TOPAMAX












      US

      45

      46

      -2.2%

      -2.2%

      -


      136

      162

      -16.0%

      -16.0%

      -

      Intl

      72

      81

      -11.1%

      -17.4%

      6.3%


      231

      255

      -9.4%

      -14.9%

      5.5%

      WW

      117

      127

      -7.9%

      -11.9%

      4.0%


      367

      417

      -12.0%

      -15.4%

      3.4%

      VELCADE












      US

      -

      -

      -

      -

      -


      -

      -

      -

      -

      -

      Intl

      295

      246

      19.9%

      11.5%

      8.4%


      922

      793

      16.3%

      9.1%

      7.2%

      WW

      295

      246

      19.9%

      11.5%

      8.4%


      922

      793

      16.3%

      9.1%

      7.2%

      OTHER












      US

      850

      653

      30.2%

      30.2%

      -


      2,377

      1,974

      20.4%

      20.4%

      -

      Intl

      1,311

      1,011

      29.7%

      21.3%

      8.4%


      3,657

      2,926

      25.0%

      17.4%

      7.6%

      WW

      2,161

      1,664

      29.9%

      24.8%

      5.1%


      6,034

      4,900

      23.1%

      18.5%

      4.6%

      TOTAL PHARMACEUTICAL












      US

      2,869

      3,054

      -6.1%

      -6.1%

      -


      9,499

      9,370

      1.4%

      1.4%

      -

      Intl

      3,113

      2,441

      27.5%

      18.5%

      9.0%


      8,775

      7,316

      19.9%

      12.1%

      7.8%

      WW

      5,982

      5,495

      8.9%

      4.9%

      4.0%


      18,274

      16,686

      9.5%

      6.1%

      3.4%

























      See footnotes at end of schedule
















      REPORTED SALES vs. PRIOR PERIOD ($MM)
















      THIRD QUARTER




      NINE MONTHS






      Total





      Total



      MAJOR NEW PHARM PRODUCTS (4)

      2011

      2010

      % Change




      2011

      2010

      % Change



      (INCLUDED IN OTHER)












      INTELENCE












      US

      42

      30

      40.0%




      118

      93

      26.9%



      Intl

      41

      37

      10.8%




      113

      85

      32.9%



      WW

      83

      67

      23.9%




      231

      178

      29.8%



      INVEGA












      US

      74

      63

      17.5%




      219

      200

      9.5%



      Intl

      52

      35

      48.6%




      155

      108

      43.5%



      WW

      126

      98

      28.6%




      374

      308

      21.4%



      SIMPONI












      US

      59

      51

      15.7%




      173

      137

      26.3%



      Intl

      70

      9

      *




      118

      24

      *



      WW

      129

      60

      *




      291

      161

      80.7%



      STELARA












      US

      112

      62

      80.6%




      317

      167

      89.8%



      Intl

      77

      38

      *




      214

      106

      *



      WW

      189

      100

      89.0%




      531

      273

      94.5%



























      See footnotes at end of schedule










































      REPORTED SALES vs. PRIOR PERIOD ($MM)


      THIRD QUARTER


      NINE MONTHS




      % Change



      % Change


      2011

      2010

      Reported

      Operational (1)

      Currency


      2011

      2010

      Reported

      Operational (1)

      Currency

      MEDICAL DEVICES AND DIAGNOSTICS   (2)












      CARDIOVASCULAR CARE (5)












      US

      198

      246

      -19.5%

      -19.5%

      -


      650

      762

      -14.7%

      -14.7%

      -

      Intl

      328

      350

      -6.3%

      -13.5%

      7.2%


      1,098

      1,161

      -5.4%

      -11.9%

      6.5%

      WW

      526

      596

      -11.7%

      -15.9%

      4.2%


      1,748

      1,923

      -9.1%

      -13.1%

      4.0%

      DEPUY












      US

      737

      748

      -1.5%

      -1.5%

      -


      2,318

      2,338

      -0.9%

      -0.9%

      -

      Intl

      647

      561

      15.3%

      6.0%

      9.3%


      2,038

      1,800

      13.2%

      4.7%

      8.5%

      WW

      1,384

      1,309

      5.7%

      1.7%

      4.0%


      4,356

      4,138

      5.3%

      1.6%

      3.7%

      DIABETES CARE












      US

      338

      338

      0.0%

      0.0%

      -


      982

      941

      4.4%

      4.4%

      -

      Intl

      326

      275

      18.5%

      9.8%

      8.7%


      1,000

      885

      13.0%

      6.1%

      6.9%

      WW

      664

      613

      8.3%

      4.4%

      3.9%


      1,982

      1,826

      8.5%

      5.2%

      3.3%

      ETHICON












      US

      519

      480

      8.1%

      8.1%

      -


      1,575

      1,499

      5.1%

      5.1%

      -

      Intl

      668

      592

      12.8%

      5.0%

      7.8%


      2,062

      1,852

      11.3%

      4.1%

      7.2%

      WW

      1,187

      1,072

      10.7%

      6.4%

      4.3%


      3,637

      3,351

      8.5%

      4.5%

      4.0%

      ETHICON ENDO-SURGERY












      US

      472

      484

      -2.5%

      -2.5%

      -


      1,433

      1,474

      -2.8%

      -2.8%

      -

      Intl

      759

      653

      16.2%

      7.6%

      8.6%


      2,314

      2,027

      14.2%

      6.4%

      7.8%

      WW

      1,231

      1,137

      8.3%

      3.4%

      4.9%


      3,747

      3,501

      7.0%

      2.5%

      4.5%

      ORTHO-CLINICAL DIAGNOSTICS












      US

      265

      263

      0.8%

      0.8%

      -


      811

      815

      -0.5%

      -0.5%

      -

      Intl

      274

      235

      16.6%

      8.7%

      7.9%


      799

      702

      13.8%

      6.4%

      7.4%

      WW

      539

      498

      8.2%

      4.5%

      3.7%


      1,610

      1,517

      6.1%

      2.7%

      3.4%

      VISION CARE












      US

      251

      241

      4.1%

      4.1%

      -


      752

      722

      4.2%

      4.2%

      -

      Intl

      501

      454

      10.4%

      1.7%

      8.7%


      1,454

      1,299

      11.9%

      3.1%

      8.8%

      WW

      752

      695

      8.2%

      2.5%

      5.7%


      2,206

      2,021

      9.2%

      3.6%

      5.6%

      TOTAL MEDICAL DEVICES AND DIAGNOSTICS












      US

      2,780

      2,800

      -0.7%

      -0.7%

      -


      8,521

      8,551

      -0.4%

      -0.4%

      -

      Intl

      3,503

      3,120

      12.3%

      3.9%

      8.4%


      10,765

      9,726

      10.7%

      3.0%

      7.7%

      WW

      6,283

      5,920

      6.1%

      1.7%

      4.4%


      19,286

      18,277

      5.5%

      1.4%

      4.1%













      * Percentage greater than 100%

      (1) Operational growth excludes the effect of currency

      (2) Select areas (unaudited)

      (3) Reported in U.S. sales

      (4) Prior year amounts have been reclassified to conform to current year product disclosure

      (5) Previously Cordis



      Johnson & Johnson and Subsidiaries














      Reconciliation of Non-GAAP Measures





























      Third Quarter


      % Incr. /



      Nine Months YTD


      % Incr. /


      (Dollars in Millions Except Per Share Data)

      2011


      2010


      (Decr.)



      2011


      2010


      (Decr.)
















      Earnings before provision for taxes on income - as reported

      $ 4,111


      4,219


      (2.6)

      %


      $ 12,043


      14,719


      (18.2)

      %















      Restructuring - Cordis

      -


      -





      676


      -


















      Net Litigation Settlements Loss (Gain) & DePuy ASR™ Hip recall costs*

      -


      -





      763


      (1,340)


















      Currency option adjustment and deal costs related to planned acquisition of Synthes

      316


      -





      214


      -


















      Earnings before provision for taxes on income - as adjusted

      $ 4,427


      4,219


      4.9

      %


      $ 13,696


      13,379


      2.4

      %















      Net Earnings - as reported

      $ 3,202


      3,417


      (6.3)

      %


      $   9,454


      11,392


      (17.0)

      %















      Restructuring - Cordis

      -


      -





      549


      -


















      Net Litigation Settlements Loss (Gain) & DePuy ASR™ Hip recall costs*

      -


      -





      596


      (977)


















      Currency option adjustment and deal costs related to planned acquisition of Synthes

      241


      -





      139


      -


















      Net Earnings - as adjusted

      $ 3,443


      3,417


      0.8

      %


      $ 10,738


      10,415


      3.1

      %















      Diluted Net earnings per share - as reported

      $   1.15


      1.23


      (6.5)

      %


      $     3.40


      4.08


      (16.7)

      %















      Restructuring - Cordis

      -


      -





      0.20


      -


















      Net Litigation Settlements Loss (Gain) & DePuy ASR™ Hip recall costs*

      -


      -





      0.22


      (0.35)


















      Currency option adjustment and deal costs related to planned acquisition of Synthes

      0.09


      -





      0.05


      -


















      Diluted Net earnings per share - as adjusted

      $   1.24


      1.23


      0.8

      %


      $     3.87


      3.73


      3.8

      %





























      *DePuy ASR™ Hip recall costs are in 2011 only.


      The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of earnings before provision for taxes on income, net earnings and diluted net earnings per share that excludes special items in order to evaluate ongoing business operations.



      SOURCE Johnson & Johnson

      Modal title

      Also from this source

      Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness

      Johnson & Johnson data in psoriatic arthritis (PsA) shows TREMFYA (guselkumab) is the only advanced therapy to demonstrate MRI-confirmed improvements in spinal pain and stiffness

      Johnson & Johnson (NYSE:JNJ) today announced late-breaking results from the Phase 4 STAR study of TREMFYA (guselkumab) in biologic-naïve adults with...

      Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication

      Johnson & Johnson Seeks U.S. FDA Approval for CAPLYTA in Bipolar Mania, Marking Fifth Potential Indication

      Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Equipment

      Medical Equipment

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.